Portugal clears Apollo's takeover of pharma group Curia
What's the deal? Portugal's competition authority, the Autoridade da Concorrência, has approved the acquisition of the Curia Group by ApolloDealroom has a profile for this one. Try Dealroom →. The green light clears the way for the private equity firm to take control of the pharmaceutical services company.
What's the endgame? Curia is a contract development and manufacturing organisation, working on behalf of pharmaceutical clients. Bringing it under Apollo gives the investor a foothold in an industry serving drugmakers.
The signal: Regulatory approval marks a routine but necessary step in closing large private equity deals in Europe. Clearance from national competition watchdogs signals confidence the transaction poses no threat to market competition.
Read more: ECO
